Clinical Research Directory
Browse clinical research sites, groups, and studies.
Enhancing Rehabilitation in Aging Study (ERAS)
Sponsor: University of Florida
Summary
Acute Intermittent Hypoxia (AIH) is a rehab approach attributed to serotonin. AIH signaling also occurs via adenosine, and the pathways inhibit each other. Increased neural adenosine in aging may stymie AIH plasticity. The hypothesis is pre-treatment with adenosine 2A receptor inhibition (A2AI) enhances AIH effects on motor plasticity in unaffected adults. AIH exposures will be paired with A2AI or placebo, with a 4-week washout. Primary outcome measures include inspiratory and grip strength.
Key Details
Gender
All
Age Range
40 Years - 79 Years
Study Type
INTERVENTIONAL
Enrollment
38
Start Date
2026-10-01
Completion Date
2031-12-31
Last Updated
2026-07-15
Healthy Volunteers
Yes
Conditions
Interventions
Istradefylline 20 mg
Participants will receive 20 mg istradefylline active treatment, followed by acute intermittent hypoxia
Placebo
Participants will receive a methylcellulose capsule identical in appearance to the active treatment, followed by acute intermittent hypoxia
Acute Intermittent Hypoxia (AIH)
Short periods (\~1 minute) of breathing lower-oxygen gas, separated by periods (\~1 minute) of breathing normal oxygen air.